Razoxane and Dexrazoxane - Two Multifunctional Agents Experimental and Clinical Results

Razoxane and dexrazoxane are two novel drugs with some uniquely useful features. They block cell division at the G2/M border, but nowhere else, so that they have a low toxicity profile. They suppress tumor metastasis and haemorrhages through normalization of pathological blood vessels. Razoxane pote...

Full description

Bibliographic Details
Other Authors: Rhomberg, Walter (Editor), Hellmann, Kurt (Editor)
Format: eBook
Language:English
Published: Dordrecht Springer Netherlands 2011, 2011
Edition:1st ed. 2011
Subjects:
Online Access:
Collection: Springer eBooks 2005- - Collection details see MPG.ReNa
LEADER 02550nmm a2200361 u 4500
001 EB000400238
003 EBX01000000000000000253291
005 00000000000000.0
007 cr|||||||||||||||||||||
008 130626 ||| eng
020 |a 9789048191680 
100 1 |a Rhomberg, Walter  |e [editor] 
245 0 0 |a Razoxane and Dexrazoxane - Two Multifunctional Agents  |h Elektronische Ressource  |b Experimental and Clinical Results  |c edited by Walter Rhomberg, Kurt Hellmann 
250 |a 1st ed. 2011 
260 |a Dordrecht  |b Springer Netherlands  |c 2011, 2011 
300 |a XIII, 243 p  |b online resource 
653 |a Neuroscience 
653 |a Neurosciences 
653 |a Internal medicine 
653 |a Cardiology 
653 |a Radiology 
653 |a Internal Medicine 
653 |a Cancer 
653 |a Cancer Biology 
653 |a Oncology 
700 1 |a Hellmann, Kurt  |e [editor] 
041 0 7 |a eng  |2 ISO 639-2 
989 |b Springer  |a Springer eBooks 2005- 
028 5 0 |a 10.1007/978-90-481-9168-0 
856 4 0 |u https://doi.org/10.1007/978-90-481-9168-0?nosfx=y  |x Verlag  |3 Volltext 
082 0 |a 616.994 
082 0 |a 571.978 
520 |a Razoxane and dexrazoxane are two novel drugs with some uniquely useful features. They block cell division at the G2/M border, but nowhere else, so that they have a low toxicity profile. They suppress tumor metastasis and haemorrhages through normalization of pathological blood vessels. Razoxane potentiates radiotherapy especially in the treatment of soft tissue sarcomas and gastrointestinal neoplasms. They protect normal tissues against toxic chemicals, e.g. the myocardium against anthracyclines or subcutaneous tissue against injuries caused by incidental extravasations of anthracyclines. Dexrazoxane is the only drug approved by the FDA/EMEA for the specific purpose of preventing cardiac damage when giving the widely used and effective antitumor anthracyclines. The reduction of cardiotoxicity is achieved without response reduction or reducing of time to progression of tumors. While the full analysis of their actions at the molecular level is not yet completely understood, it seems most likely that it is via an inhibition on the topoisomerase II a. Moreover, the drugs have the ability to chelate several metals including iron, copper or zinc. The protection of normal tissues is nowhere more important than that of brain, and there are indications that the proteins thought to be responsible for the ravages of Alzheimer´s disease could be stabilized by one or both these drugs